Advertisement
Australia markets close in 4 hours 45 minutes
  • ALL ORDS

    8,042.50
    -75.80 (-0.93%)
     
  • ASX 200

    7,769.40
    -78.70 (-1.00%)
     
  • AUD/USD

    0.6618
    -0.0003 (-0.04%)
     
  • OIL

    76.98
    -0.59 (-0.76%)
     
  • GOLD

    2,379.30
    -13.60 (-0.57%)
     
  • Bitcoin AUD

    104,848.24
    -1,080.73 (-1.02%)
     
  • CMC Crypto 200

    1,507.83
    -18.58 (-1.22%)
     
  • AUD/EUR

    0.6112
    +0.0002 (+0.03%)
     
  • AUD/NZD

    1.0840
    -0.0019 (-0.17%)
     
  • NZX 50

    11,737.87
    +5.59 (+0.05%)
     
  • NASDAQ

    18,705.20
    -8.59 (-0.05%)
     
  • FTSE

    8,370.33
    -46.12 (-0.55%)
     
  • Dow Jones

    39,671.04
    -201.95 (-0.51%)
     
  • DAX

    18,680.20
    -46.56 (-0.25%)
     
  • Hang Seng

    19,195.60
    0.00 (0.00%)
     
  • NIKKEI 225

    38,838.18
    +221.08 (+0.57%)
     

The Zacks Analyst Blog Highlights AbbVie, Salesforce, General Electric, The TJX Companies and UBS Group

For Immediate Release

Chicago, IL – April 10, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. ABBV, Salesforce, Inc. CRM, General Electric Co. GE, The TJX Companies, Inc. TJX and UBS Group AG UBS.

Here are highlights from Tuesday’s Analyst Blog:

Top Stock Reports for AbbVie, Salesforce and General Electric

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc., Salesforce, Inc. and General Electric Co. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today's research reports here >>>

AbbVie's shares have modestly outperformed the Zacks Large Cap Pharmaceuticals industry over the past six months (+16.3% vs. +15%) on the back of optimism about the company's portfolio of new drugs.

Newer products, Skyrizi and Rinvoq, are performing extremely well, bolstered by approval in new indications, which should support top-line growth in the next few years. AbbVie has several early/mid-stage candidates that have the potential to drive long-term growth. Though revenues declined in 2023, AbbVie expects to return to robust sales growth in 2025.

However, the company faces several near-term headwinds like Humira's biosimilar erosion, increasing competitive pressure on Imbruvica and weakness in fillers. Estimates have risen slightly ahead of Q1 earnings. AbbVie has a positive record of earnings surprises in recent quarters.

(You can read the full research report on AbbVie here >>>)

Shares of Salesforce have outperformed the Zacks Computer - Software industry over the past year (+57.8% vs. +44%). The company is benefiting from a robust demand environment as customers are undergoing a major digital transformation. Its sustained focus on aligning products with customer needs is driving the top line.

Continued deal wins in the international market are another growth driver. The buyout of Slack has positioned the company as a leader in enterprise team collaboration and improved its competitive standing versus Microsoft Teams. Salesforce's strategy of continuously expanding generative AI offerings will help it tap the growing opportunities in the space.

However, stiff competition and unfavorable currency fluctuations are concerns. Also, softening IT spending amid the ongoing macroeconomic uncertainties could hurt its growth prospects.

(You can read the full research report on Salesforce here >>>)

General Electric shares have significantly outperformed the Zacks Diversified Operations industry over the past year (+66.2% vs. +11.3%) reflecting the value unlocked by the company's restructuring. The company has been witnessing strength in its Aerospace business, driven by robust demand for commercial engines and services. Rising U.S. & international defense budgets, geopolitical tensions, positive airline & airframer dynamics and robust demand for commercial air travel augur well for the company.

General Electric's portfolio reshaping actions are likely to unlock values for its shareholders. GE Aerospace's shareholder-friendly policies are also encouraging. Shares of the company have outperformed the industry in the past six months.

However, it has been dealing with high costs and expenses related to certain projects and restructuring activities, which might affect its margins and profitability. Supply-chain disruptions in the defense market continue to take a toll on its operations. Also, foreign exchange headwinds might be worrying.

(You can read the full research report on General Electric here >>>)

Other noteworthy reports we are featuring today include The TJX Companies, Inc. and UBS Group AG.

ADVERTISEMENT

Why Haven't You Looked at Zacks' Top Stocks?

Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.

Today you can access their live picks without cost or obligation.

See Stocks Free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                       

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

General Electric Company (GE) : Free Stock Analysis Report

Salesforce Inc. (CRM) : Free Stock Analysis Report

The TJX Companies, Inc. (TJX) : Free Stock Analysis Report

UBS Group AG (UBS) : Free Stock Analysis Report

AbbVie Inc. (ABBV) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research